biostudies-literatureAker MNJean Perkins FoundationNCATS NIH HHSNational Cancer InstituteNCI NIH HHSProstate Cancer FoundationClinical and Translational Science Institute, University of California, Los AngelesPhase One Foundation9351-9362https://www.ebi.ac.uk/biostudies/studies/S-EPMC10166973biostudies-literatureUnknown12(8)<h4>Background</h4>Partial gland ablation (PGA) is a new option for treatment of prostate cancer (PCa). Cryotherapy, an early method of PGA, has had favorable evaluations, but few studies have employed a strict protocol using biopsy endpoints in men with clinically significant prostate cancer (csPCa).<h4>Methods</h4>143 men with unilateral csPCa were enrolled in a prospective, observational trial of outpatient PGA-cryotherapy. Treatment was a 2-cycle freeze of the affected prostate part. Participants were evaluated with MRI-guided biopsy (MRGB) at baseline and at 6 months and 18 months after treatment. Absence of csPCa upon MRGB was the primary endpoint; quality-of-life at baseline and at 6 months after treatment was assessed by EPIC-CP questionnaires in the domains of urinary and sexual fCancer medicineCryotherapy for partial gland ablation of prostate cancer: Oncologic and safety outcomes.PMC10166973UL1TR000124R01CA195505UL1 TR000124UL1 TR001881Sisk AEKwan LDelfin MKKuppermann DAker MNPriester AMFelker EBrisbane WGMarks LSGonzalez SKinnaird AfalseCryotherapy for partial gland ablation of prostate cancer: Oncologic and safety outcomes.<h4>Background</h4>Partial gland ablation (PGA) is a new option for treatment of prostate cancer (PCa). Cryotherapy, an early method of PGA, has had favorable evaluations, but few studies have employed a strict protocol using biopsy endpoints in men with clinically significant prostate cancer (csPCa).<h4>Methods</h4>143 men with unilateral csPCa were enrolled in a prospective, observational trial of outpatient PGA-cryotherapy. Treatment was a 2-cycle freeze of the affected prostate part. Participants were evaluated with MRI-guided biopsy (MRGB) at baseline and at 6 months and 18 months after treatment. Absence of csPCa upon MRGB was the primary endpoint; quality-of-life at baseline and at 6 months after treatment was assessed by EPIC-CP questionnaires in the domains of urinary and sexual f2023-01-01T00:00:00Z2023 Apr2026-07-14T21:16:32.074Z2025-04-05T10:54:46.882ZS-EPMC101669733677592910.1002/cam4.5692